ReviewInternational journal of molecular sciences2026
Artificial Intelligence in Pediatric Cardiovascular Genetics: From Multimodal Diagnosis to Risk Prediction and Precision Therapeutics.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) is increasingly being explored as a bridge between high-dimensional cardiovascular phenotyping and genomic interpretation in children with inherited and congenital heart disease. This review focuses specifically on where AI-assisted approaches in pediatric cardiovascular genetics have progressed beyond proof-of-concept, how the maturity of evidence differs between general genomic tools and pediatric cardiovascular applications, and what is required for responsible clinical translation. Inherited and rare cardiovascular disorders are characterized by genetic heterogeneity, incomplete penetrance, variable expressivity, and age-dependent phenotypes, while modern sequencing, imaging, and longitudinal monitoring generate data that are difficult to integrate using conventional approaches alone. AI-assisted methods are being investigated across diagnostic, prognostic, and therapeutic domains, including computational phenotyping, genomic variant prioritization, electrocardiographic and imaging analysis, multimodal risk prediction, and selection of candidates for precision therapies. The strongest pediatric cardiovascular evidence currently comes from externally evaluated ECG and echocardiographic models and from large outcome-prediction cohorts, whereas many genomic tools-including variant callers and pathogenicity predictors-remain general-purpose methods that have not been specifically validated in pediatric cardiovascular genetics. Recent disease-specific genomic models and automated reanalysis frameworks illustrate a shift toward more clinically contextualized interpretation, but current evidence remains limited by retrospective design, small or selectively assembled rare-disease cohorts, domain shift, population bias, incomplete calibration, and uncertain clinical utility. Accordingly, AI should be viewed as a governed decision-support layer rather than an autonomous authority. With external validation, transparent reporting, longitudinal monitoring, and multidisciplinary oversight, AI has the potential to augment specialist expertise and may support earlier diagnosis, improved risk stratification, and more individualized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.